

Ethan M Basch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9006953/publications.pdf>

Version: 2024-02-01

294
papers

31,428
citations

8181

76
h-index

4885

168
g-index

300
all docs

300
docs citations

300
times ranked

29187
citing authors

#	ARTICLE	IF	CITATIONS
1	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	27.0	2,412
2	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1148-1159.	1.6	1,960
3	Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 557-565.	1.6	1,746
4	Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 197.	7.4	1,509
5	Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 96-112.	1.6	1,454
6	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	1.6	1,089
7	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2011, 29, 4189-4198.	1.6	822
8	Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of the National Cancer Institute</i> , 2014, 106, dju244-dju244.	6.3	689
9	Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>JAMA Oncology</i> , 2015, 1, 1051.	7.1	581
10	The Missing Voice of Patients in Drug-Safety Reporting. <i>New England Journal of Medicine</i> , 2010, 362, 865-869.	27.0	524
11	Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1624-1632.	6.3	514
12	Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. <i>Lancet Oncology</i> , The, 2006, 7, 903-909.	10.7	512
13	Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 483.	7.4	507
14	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3240-3261.	1.6	454
15	Recommendations on Evidence Needed to Support Measurement Equivalence between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures: ISPOR ePRO Good Research Practices Task Force Report. <i>Value in Health</i> , 2009, 12, 419-429.	0.3	430
16	Patient-Reported Outcomes "Harnessing Patients' Voices to Improve Clinical Care. <i>New England Journal of Medicine</i> , 2017, 376, 105-108.	27.0	426
17	The PCORI Perspective on Patient-Centered Outcomes Research. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1513.	7.4	424
18	Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology. <i>Journal of Clinical Oncology</i> , 2012, 30, 4249-4255.	1.6	413

#	ARTICLE	IF	CITATIONS
19	Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 306.	7.4	363
20	Bitter melon (<i>Momordica charantia</i>): A review of efficacy and safety. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 356-359.	1.0	304
21	Sorafenib for Advanced and Refractory Desmoid Tumors. <i>New England Journal of Medicine</i> , 2018, 379, 2417-2428.	27.0	287
22	Electronic patient-reported outcome systems in oncology clinical practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 336-347.	329.8	279
23	Patient-Reported Outcomes and the Evolution of Adverse Event Reporting in Oncology. <i>Journal of Clinical Oncology</i> , 2007, 25, 5121-5127.	1.6	278
24	Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 3552-3561.	1.6	267
25	Implementation of Patient-Reported Outcomes in Routine Medical Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 122-134.	3.8	260
26	Review of Electronic Patient-Reported Outcomes Systems Used in Cancer Clinical Care. <i>Journal of Oncology Practice</i> , 2014, 10, e215-e222.	2.5	257
27	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 1210-1217.	10.7	254
28	The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. <i>Supportive Care in Cancer</i> , 2016, 24, 3669-3676.	2.2	249
29	A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. <i>Supportive Care in Cancer</i> , 2013, 21, 1525-1550.	2.2	248
30	American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 3388-3404.	1.6	246
31	Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju129-dju129.	6.3	245
32	Oncology Practice During the COVID-19 Pandemic. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2005.	7.4	221
33	Using Confirmatory Factor Analysis to Evaluate Construct Validity of the Brief Pain Inventory (BPI). <i>Journal of Pain and Symptom Management</i> , 2011, 41, 558-565.	1.2	217
34	End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice. <i>Journal of Clinical Oncology</i> , 2011, 29, 3695-3704.	1.6	202
35	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3436-3448.	1.6	201
36	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 2782-2797.	1.6	201

#	ARTICLE	IF	CITATIONS
37	Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 67-73.	3.8	196
38	Reliability of adverse symptom event reporting by clinicians. Quality of Life Research, 2012, 21, 1159-1164.	3.1	186
39	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncology, The, 2014, 15, 1147-1156.	10.7	181
40	International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncology, The, 2020, 21, e83-e96.	10.7	180
41	Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nature Reviews Clinical Oncology, 2016, 13, 319-325.	27.6	179
42	Long-Term Toxicity Monitoring via Electronic Patient-Reported Outcomes in Patients Receiving Chemotherapy. Journal of Clinical Oncology, 2007, 25, 5374-5380.	1.6	173
43	Antiemetics: American Society of Clinical Oncology Focused Guideline Update. Journal of Clinical Oncology, 2016, 34, 381-386.	1.6	173
44	Use of information resources by patients with cancer and their companions. Cancer, 2004, 100, 2476-2483.	4.1	164
45	The Brief Pain Inventory and Its "Pain At Its Worst in the Last 24 Hours" Item: Clinical Trial Endpoint Considerations. Pain Medicine, 2010, 11, 337-346.	1.9	161
46	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncology, The, 2016, 17, e510-e514.	10.7	158
47	Therapeutic applications of fenugreek. Alternative Medicine Review, 2003, 8, 20-7.	3.3	155
48	Models of Cancer Survivorship Care: Overview and Summary of Current Evidence. Journal of Oncology Practice, 2015, 11, e19-e27.	2.5	148
49	American Society of Clinical Oncology Clinical Practice Guidelines: Formal Systematic Review "Based Consensus Methodology. Journal of Clinical Oncology, 2012, 30, 3136-3140.	1.6	146
50	A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive Care in Cancer, 2010, 18, 509-522.	2.2	142
51	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 1193-1199.	10.7	142
52	Feasibility of Long-Term Patient Self-Reporting of Toxicities From Home via the Internet During Routine Chemotherapy. Journal of Clinical Oncology, 2013, 31, 2580-2585.	1.6	134
53	Supporting Clinical Practice Decisions With Real-Time Patient-Reported Outcomes. Journal of Clinical Oncology, 2011, 29, 954-956.	1.6	124
54	Toward Patient-Centered Drug Development in Oncology. New England Journal of Medicine, 2013, 369, 397-400.	27.0	118

#	ARTICLE	IF	CITATIONS
55	Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Quality of Life Research</i> , 2014, 23, 257-269.	3.1	117
56	Standards for Patient-Reported Outcome-Based Performance Measures. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 139.	7.4	115
57	New Frontiers in Patient-Reported Outcomes: Adverse Event Reporting, Comparative Effectiveness, and Quality Assessment. <i>Annual Review of Medicine</i> , 2014, 65, 307-317.	12.2	112
58	St. John's Wort: A Systematic Review of Adverse Effects and Drug Interactions for the Consultation Psychiatrist. <i>Psychosomatics</i> , 2003, 44, 271-282.	2.5	110
59	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3391-3399.	1.6	110
60	Evaluation of an Online Platform for Cancer Patient Self-reporting of Chemotherapy Toxicities. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2007, 14, 264-268.	4.4	108
61	Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2413.	7.4	108
62	Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. <i>JAMA Oncology</i> , 2016, 2, 1628.	7.1	106
63	Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review. <i>JAMA Oncology</i> , 2015, 1, 375.	7.1	105
64	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1404-1416.	10.7	105
65	Methods for Developing Patient-Reported Outcome-Based Performance Measures (PRO-PMs). <i>Value in Health</i> , 2015, 18, 493-504.	0.3	103
66	Use of Patient-Reported Outcomes to Improve the Predictive Accuracy of Clinician-Reported Adverse Events. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1808-1810.	6.3	99
67	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. <i>JAMA Oncology</i> , 2017, 3, 1043.	7.1	98
68	Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 947-957.	2.1	97
69	Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 517.	2.2	93
70	Guggul for hyperlipidemia: A review by the Natural Standard Research Collaboration. <i>Complementary Therapies in Medicine</i> , 2005, 13, 279-290.	2.7	91
71	Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. <i>European Urology</i> , 2015, 68, 891-898.	1.9	91
72	Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Health and Quality of Life Outcomes</i> , 2016, 14, 24.	2.4	91

#	ARTICLE	IF	CITATIONS
73	Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 409-418.	0.8	87
74	Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1012-1020.	1.1	85
75	Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium Guidance. <i>Drug Safety</i> , 2013, 36, 1129-1149.	3.2	84
76	A Strategy To Advance the Evidence Base in Palliative Medicine: Formation of a Palliative Care Research Cooperative Group. <i>Journal of Palliative Medicine</i> , 2010, 13, 1407-1413.	1.1	81
77	Return to work in low-income Latina and non-Latina white breast cancer survivors: A 3-year longitudinal study. <i>Cancer</i> , 2012, 118, 1664-1674.	4.1	81
78	Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Clinical Trials</i> , 2021, 18, 104-114.	1.6	80
79	Targeted drugs for metastatic renal cell carcinoma. <i>Lancet</i> , The, 2007, 370, 2071-2073.	13.7	79
80	Patient-Reported Outcome Performance Measures in Oncology. <i>Journal of Oncology Practice</i> , 2014, 10, 209-211.	2.5	79
81	The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data. <i>Oncologist</i> , 2015, 20, 464-e20.	3.7	79
82	Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. <i>Value in Health</i> , 2018, 21, 742-747.	0.3	79
83	Emerging uses of patient generated health data in clinical research. <i>Molecular Oncology</i> , 2015, 9, 1018-1024.	4.6	77
84	Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. <i>Clinical Therapeutics</i> , 2016, 38, 821-830.	2.5	77
85	An Evidence-Based Systematic Review of Elderberry and Elderflower (<i>Sambucus nigra</i>) by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2014, 11, 80-120.	2.6	75
86	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1518-1530.	10.7	69
87	A Review of Quality of Care Evaluation for the Palliation of Dyspnea. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 534-538.	5.6	68
88	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. <i>Lancet Oncology</i> , The, 2018, 19, e459-e469.	10.7	66
89	American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5313-5318.	1.6	65
90	A prospective study of the feasibility and acceptability of a Web-based, electronic patient-reported outcome system in assessing patient recovery after major gynecologic cancer surgery. <i>Gynecologic Oncology</i> , 2012, 127, 273-277.	1.4	65

#	ARTICLE	IF	CITATIONS
91	Patients' Responsibility to Participate in Decision Making and Research. JAMA - Journal of the American Medical Association, 2013, 309, 2331.	7.4	65
92	Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. Cancer, 2019, 125, 2945-2954.	4.1	60
93	Validation study of a web-based assessment of functional recovery after radical prostatectomy. Health and Quality of Life Outcomes, 2010, 8, 82.	2.4	59
94	Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes. Nature Reviews Drug Discovery, 2019, 18, 731-732.	46.4	59
95	Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opinion on Drug Safety, 2005, 4, 779-794.	2.4	58
96	Against Diagnosis. Annals of Internal Medicine, 2008, 149, 200.	3.9	58
97	Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. Clinical Trials, 2017, 14, 255-263.	1.6	58
98	Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB) Tj ETQq0 0 0 rgt /Overlook 10 Tf 5		
99	Symptom Monitoring in Pediatric Oncology Using Patient-Reported Outcomes: Why, How, and Where Next. Patient, 2018, 11, 147-153.	2.7	57
100	Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. Oncologist, 2019, 24, 762-771.	3.7	56
101	Evaluation of pedometry as a patient-centered outcome in patients undergoing hematopoietic cell transplant (HCT): a comparison of pedometry and patient reports of symptoms, health, and quality of life. Quality of Life Research, 2016, 25, 535-546.	3.1	54
102	Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 67-73.	3.8	54
103	Trustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials. JAMA Oncology, 2017, 3, 738.	7.1	53
104	Second-Line Hormonal Therapy for Men With Chemotherapy-Na ⁺ -ve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. Journal of Clinical Oncology, 2017, 35, 1952-1964.	1.6	53
105	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Oncology Practice, 2011, 7, 395-398.	2.5	52
106	Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients. Journal of Patient-Reported Outcomes, 2017, 1, 1.	1.9	52
107	Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). Clinical Trials, 2019, 16, 165-175.	1.6	52
108	The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Quality of Life Research, 2017, 26, 2763-2772.	3.1	51

#	ARTICLE	IF	CITATIONS
109	Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1521-1539.	1.6	51
110	Marigold (<i>Calendula officinalis</i> L.). <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2006, 6, 135-159.	0.1	50
111	Beyond the FDA PRO Guidance: Steps toward Integrating Meaningful Patient-Reported Outcomes into Regulatory Trials and US Drug Labels. <i>Value in Health</i> , 2012, 15, 401-403.	0.3	48
112	Use of mobile device technology to continuously collect patient-reported symptoms during radiation therapy for head and neck cancer: A prospective feasibility study. <i>Advances in Radiation Oncology</i> , 2016, 1, 115-121.	1.2	48
113	Patient-Reported Outcomes in Clinical Trials of Rare Diseases. <i>Journal of General Internal Medicine</i> , 2014, 29, 801-803.	2.6	47
114	Electronic Toxicity Monitoring and Patient-Reported Outcomes. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 231-234.	2.0	46
115	Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 276-285.	4.4	46
116	Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. <i>Journal of Clinical Oncology</i> , 2018, 36, 3120-3125.	1.6	45
117	Feasibility of Frequent Patient-Reported Outcome Surveillance in Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 450-459.	2.0	44
118	The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review. <i>Supportive Care in Cancer</i> , 2015, 23, 3645-3652.	2.2	44
119	Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of Patient-Reported Outcomes</i> , 2017, 1, 8.	1.9	44
120	Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Translational Behavioral Medicine</i> , 2011, 1, 110-122.	2.4	43
121	Big Data for Population-Based Cancer Research. <i>North Carolina Medical Journal</i> , 2014, 75, 265-269.	0.2	43
122	Geriatric Assessment as a Predictor of Tolerance, Quality of Life, and Outcomes in Older Patients With Head and Neck Cancers and Lung Cancers Receiving Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 850-857.	0.8	43
123	Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. <i>Clinical Trials</i> , 2018, 15, 624-630.	1.6	42
124	Incorporating the patient's voice into electronic health records through patient-reported outcomes as the "coreview of systems". <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 914-916.	4.4	41
125	Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of life. <i>Gynecologic Oncology</i> , 2016, 143, 362-366.	1.4	41
126	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. <i>European Urology</i> , 2019, 75, 929-937.	1.9	41

#	ARTICLE	IF	CITATIONS
127	Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. <i>Clinical Trials</i> , 2016, 13, 331-337.	1.6	40
128	Using Stakeholder Engagement to Overcome Barriers to Implementing Patient-reported Outcomes (PROs) in Cancer Care Delivery. <i>Medical Care</i> , 2019, 57, S92-S99.	2.4	40
129	Potential and Challenges of Patient-Generated Health Data for High-Quality Cancer Care. <i>Journal of Oncology Practice</i> , 2015, 11, 195-197.	2.5	39
130	Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. <i>JAMA Oncology</i> , 2020, 6, e193332.	7.1	39
131	Harnessing Technology to Improve Clinical Trials: Study of Real-Time Informatics to Collect Data, Toxicities, Image Response Assessments, and Patient-Reported Outcomes in a Phase II Clinical Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2004-2009.	1.6	38
132	Considerations for extrapolating evidence of acute and chronic pain analgesic efficacy. <i>Pain</i> , 2011, 152, 1705-1708.	4.2	36
133	Missing Patientsâ€™ Symptoms in Cancer Care Deliveryâ€™The Importance of Patient-Reported Outcomes. <i>JAMA Oncology</i> , 2016, 2, 433.	7.1	36
134	Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 735-743.	2.5	36
135	The Japanese version of the National Cancer Instituteâ€™s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 2.	1.9	36
136	Adding Patient-Reported Outcomes to Medicareâ€™s Oncology Value-Based Payment Model. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 213.	7.4	36
137	An evidence-based systematic review of herb and supplement interactions by the Natural Standard Research Collaboration. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 719-728.	2.4	35
138	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	1.9	35
139	Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 759-766.	1.2	35
140	Older Adults with Cancer: A Randomized Controlled Trial of Occupational and Physical Therapy. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 953-960.	2.6	35
141	The Evolving Uses of â€œReal-Worldâ€œData. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1359.	7.4	35
142	Decreasing the Adverse Effects of Cancer Therapy: National Cancer Institute Guidance for the Clinical Development of Radiation Injury Mitigators. <i>Clinical Cancer Research</i> , 2011, 17, 222-228.	7.0	34
143	Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?. <i>Seminars in Oncology</i> , 2013, 40, 375-392.	2.2	34
144	Implementation of Electronic Patient-Reported Outcomes for Symptom Monitoring in a Large Multisite Community Oncology Practice: Dancing the Texas Two-Step Through a Pandemic. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 615-621.	2.1	34

#	ARTICLE	IF	CITATIONS
145	Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of Pain and Symptom Management</i> , 2016, 52, 292-297.	1.2	32
146	The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 460-466.	3.8	31
147	Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws. <i>JAMA Oncology</i> , 2018, 4, e173598.	7.1	31
148	Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 44-52.	0.8	31
149	Patient-reported outcomes: an essential component of oncology drug development and regulatory review. <i>Lancet Oncology</i> , The, 2018, 19, 595-597.	10.7	30
150	The king's foot of patient-reported outcomes: current practices and new developments for the measurement of change. <i>Quality of Life Research</i> , 2011, 20, 1159-1167.	3.1	29
151	Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure. <i>Journal of Oncology Practice</i> , 2013, 9, 223-229.	2.5	29
152	Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective. <i>Cancer</i> , 2014, 120, 761-767.	4.1	29
153	Patient-Reported Physical Function Measures in Cancer Clinical Trials. <i>Epidemiologic Reviews</i> , 2017, 39, 59-70.	3.5	29
154	Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. <i>British Journal of Cancer</i> , 2018, 119, 801-807.	6.4	29
155	How Do You Know If You Are Any Good? A Surgeon Performance Feedback System for the Outcomes of Radical Prostatectomy. <i>European Urology</i> , 2012, 61, 284-289.	1.9	28
156	The Rationale for Collecting Patient-Reported Symptoms during Routine Chemotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 161-165.	3.8	28
157	Leveraging Emerging Technologies and the "Internet of Things" to Improve the Quality of Cancer Care. <i>Journal of Oncology Practice</i> , 2016, 12, 863-866.	2.5	28
158	Toward a Patient-Centered Value Framework in Oncology. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2073.	7.4	28
159	Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Supportive Care in Cancer</i> , 2016, 24, 2843-2851.	2.2	28
160	Association Between Reimbursement Incentives and Physician Practice in Oncology. <i>JAMA Oncology</i> , 2019, 5, 893.	7.1	28
161	The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 460-466.	3.8	28
162	Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Oncology Nursing</i> , 2015, 19, 66-74.	2.1	27

#	ARTICLE	IF	CITATIONS
163	Boswellia: an evidence-based systematic review by the Natural Standard Research Collaboration. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2004, 4, 63-83.	0.1	27
164	Using patient-reported outcome measures as quality indicators in routine cancer care. Cancer, 2016, 122, 355-357.	4.1	26
165	Translating Cancer Surveillance Data Into Effective Public Health Interventions. JAMA - Journal of the American Medical Association, 2017, 317, 365.	7.4	25
166	Congruence of patient and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. Cancer, 2020, 126, 3084-3093.	4.1	25
167	Antiemetic Use in Oncology: Updated Guideline Recommendations from ASCO. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 532-540.	3.8	24
168	Ambulatory cancer care electronic symptom self-reporting (ACCESS) for surgical patients: a randomised controlled trial protocol. BMJ Open, 2019, 9, e030863.	1.9	24
169	Thyme (Thymus vulgaris L.), thymol. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2004, 4, 49-67.	0.1	24
170	Comparative Patient-Centered Outcomes (Health State and Adverse Sexual Symptoms) Between Adjuvant Brachytherapy Versus No Adjuvant Brachytherapy in Early Stage Endometrial Cancer. Annals of Surgical Oncology, 2014, 21, 2740-2754.	1.5	23
171	Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure. Oncologist, 2015, 20, 516-522.	3.7	23
172	Gynecologic cancer outcomes in the elderly poor: A population-based study. Cancer, 2015, 121, 3591-3599.	4.1	22
173	Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials. JAMA Oncology, 2020, 6, 437.	7.1	22
174	Electronic Patient-Reported Outcomes as Digital Therapeutics to Improve Cancer Outcomes. JCO Oncology Practice, 2020, 16, 541-542.	2.9	22
175	Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. Clinical Genitourinary Cancer, 2009, 7, 51-57.	1.9	21
176	An Evidence-Based Systematic Review of Bilberry (<i>Vaccinium myrtillus</i>) by the Natural Standard Research Collaboration. Journal of Dietary Supplements, 2009, 6, 162-200.	2.6	20
177	Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data. Expert Opinion on Drug Discovery, 2016, 11, 753-758.	5.0	20
178	Patient reported symptoms associated with quality of life during chemo or immunotherapy for bladder cancer patients with advanced disease. Cancer Medicine, 2020, 9, 3078-3087.	2.8	20
179	Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. JMIR Human Factors, 2018, 5, e10070.	2.0	20
180	An Evidence-Based Systematic Review of Belladonna by the Natural Standard Research Collaboration. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2004, 4, 61-90.	0.1	19

#	ARTICLE	IF	CITATIONS
181	Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. <i>JAMA Oncology</i> , 2018, 4, 580.	7.1	19
182	eSyM: An Electronic Health Recordâ€“Integrated Patient-Reported Outcomesâ€“Based Cancer Symptom Management Program Used by Six Diverse Health Systems. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100137.	2.1	19
183	Assuring the Patient Centeredness of Patient-Reported Outcomes: Content Validity in Medical Product Development and Comparative Effectiveness Research. <i>Value in Health</i> , 2011, 14, 965-966.	0.3	18
184	Capturing the Patient Perspective: Patient-Reported Outcomes as Clinical Trial Endpoints. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 139-144.	3.8	18
185	All together now: findings from a PCORI workshop to align patient-reported outcomes in the electronic health record. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 561-567.	1.4	18
186	Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1541.	7.4	18
187	Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. <i>Pain Medicine</i> , 2012, 13, 1417-1424.	1.9	17
188	Itâ€™s a long shot, but it just might work! Perspectives on the future of medicine. <i>BMC Medicine</i> , 2016, 14, 176.	5.5	17
189	High Compliance Rates With Patient-Reported Outcomes in Oncology Trials Submitted to the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2019, 111, 437-439.	6.3	17
190	Electronic symptom monitoring in pediatric patients hospitalized for chemotherapy. <i>Cancer</i> , 2021, 127, 2980-2989.	4.1	17
191	Electronic patient-reported outcomes for collecting sensitive information from patients. <i>The Journal of Supportive Oncology</i> , 2009, 7, 98-9.	2.3	17
192	An Evidence-Based Systematic Review of <i>Gymnema</i> (<i>Gymnema sylvestre</i> R. Br.) by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2011, 8, 311-330.	2.6	16
193	Systematic Collection of Patient-Reported Adverse Drug Reactions: A Path to Patient-Centred Pharmacovigilance. <i>Drug Safety</i> , 2013, 36, 277-278.	3.2	16
194	Benefits of Digital Symptom Monitoring With Patient-Reported Outcomes During Adjuvant Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2021, 39, 701-703.	1.6	16
195	Evidence-based systematic review of dandelion (<i>Taraxacum officinale</i>) by natural standard research collaboration. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2005, 5, 79-93.	0.1	16
196	Commentary: Encouraging Clinicians to Incorporate Longitudinal Patient-Reported Symptoms in Routine Clinical Practice. <i>Journal of Oncology Practice</i> , 2011, 7, 23-25.	2.5	15
197	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 386.e1-386.e6.	1.6	15
198	Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 424-432.	0.9	15

#	ARTICLE	IF	CITATIONS
199	Population-level evidence of survival benefits of patient-reported outcome symptom monitoring software systems in routine cancer care. <i>Cancer Medicine</i> , 2020, 9, 7797-7799.	2.8	15
200	Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). <i>Clinical Genitourinary Cancer</i> , 2020, 18, 378-386.e1.	1.9	15
201	Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 351-359.	2.5	14
202	Patient-Reported Outcomes for Tolerability Assessment in Phase I Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 943-944.	6.3	14
203	Broadened Eligibility for Lung Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 939.	7.4	14
204	A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring. <i>Current Oncology</i> , 2022, 29, 4370-4385.	2.2	14
205	Evaluation of mode equivalence of the MSKCC Bowel Function Instrument, LASA Quality of Life, and Subjective Significance Questionnaire items administered by Web, interactive voice response system (IVRS), and paper. <i>Quality of Life Research</i> , 2016, 25, 1123-1130.	3.1	13
206	Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017. <i>JAMA Oncology</i> , 2019, 5, 1358.	7.1	13
207	Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. <i>European Urology Oncology</i> , 2020, 3, 540-543.	5.4	13
208	Lemon balm (<i>Melissa officinalis</i> L.): an evidence-based systematic review by the Natural Standard Research Collaboration. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2005, 5, 71-114.	0.1	13
209	Implementation of Symptom Questionnaires Into Oncology Workflow. <i>Journal of Oncology Practice</i> , 2016, 12, 859-862.	2.5	12
210	Racial differences in user experiences and perceived value of electronic symptom monitoring in a cohort of black and white bladder and prostate cancer patients. <i>Quality of Life Research</i> , 2021, 30, 3213-3227.	3.1	12
211	Peppermint (<i>Mentha Xpiperita</i>). <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2008, 7, 91-143.	0.1	11
212	Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients. <i>Supportive Care in Cancer</i> , 2016, 24, 4839-4847.	2.2	11
213	Evidence-Based Systematic Review of Saw Palmetto by the Natural Standard Research Collaboration*. <i>Society for Integrative Oncology</i> , 2006, 04, 170.	0.7	11
214	Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD). <i>Cancer</i> , 2022, 128, 1242-1251.	4.1	11
215	Comparison of Seven-Day and Repeated 24-Hour Recall of Symptoms in the First 100 Days After Hematopoietic Cell Transplantation. <i>Journal of Pain and Symptom Management</i> , 2015, 49, 513-520.	1.2	10
216	Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina. <i>Cancer</i> , 2016, 122, 3041-3050.	4.1	10

#	ARTICLE	IF	CITATIONS
217	The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery. <i>Current Oncology Reports</i> , 2017, 19, 12.	4.0	10
218	Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2019, 27, 4525-4534.	2.2	10
219	Devil's Claw (<i>Harpagophytum procumbens</i> DC): an evidence-based systematic review by the Natural Standard Research Collaboration. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2006, 6, 89-126.	0.1	10
220	Prostate-Specific Antigen Test for Prostate Cancer Screening: American Society of Clinical Oncology Provisional Clinical Opinion. <i>Journal of Oncology Practice</i> , 2012, 8, 315-317.	2.5	9
221	An Evidence-Based Systematic Review of Vitamin A by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2012, 9, 299-416.	2.6	9
222	Clinical Benefits Associated With Medicaid Coverage Before Diagnosis of Gynecologic Cancers. <i>Journal of Oncology Practice</i> , 2016, 12, e724-e733.	2.5	9
223	Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1055-1062.	6.3	9
224	Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39). <i>Lung Cancer</i> , 2021, 162, 1-8.	2.0	9
225	Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 148-154.	0.1	9
226	An Exploratory Analysis of the "Was It Worth It?" Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment. <i>Value in Health</i> , 2022, 25, 1081-1086.	0.3	9
227	Natural Standard Professional Monograph. <i>Journal of Dietary Supplements</i> , 2008, 5, 117-146.	2.6	8
228	Relationship between sleep and exercise as colorectal cancer survivors transition off treatment. <i>Supportive Care in Cancer</i> , 2018, 26, 2663-2673.	2.2	8
229	The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD. <i>BMC Cancer</i> , 2018, 18, 788.	2.6	8
230	Improving patient-reported measures in oncology: a payer call to action. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 118-126.	0.9	8
231	An evidence-based systematic review of belladonna by the natural standard research collaboration. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2004, 4, 61-90.	0.1	8
232	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2014, 10, e418-e420.	2.5	7
233	Big Data Infrastructure for Cancer Outcomes Research: Implications for the Practicing Oncologist. <i>Journal of Oncology Practice</i> , 2015, 11, 207-208.	2.5	7
234	From Intuition to Execution: Realizing the Potential of Wearables in Oncology. <i>Journal of Oncology Practice</i> , 2017, 13, 90-92.	2.5	7

#	ARTICLE	IF	CITATIONS
235	Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer Centers. <i>JCO Oncology Practice</i> , 2020, 16, e234-e250.	2.9	7
236	The association between patient experience and healthcare outcomes using SEER-CAHPS patient experience and outcomes among cancer survivors. <i>Journal of Geriatric Oncology</i> , 2021, 12, 623-631.	1.0	7
237	Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. <i>Cancer</i> , 2021, 127, 957-967.	4.1	7
238	Alfalfa (<i>Medicago sativa</i> L.). <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2003, 3, 69-90.	0.1	7
239	Horse chestnut: a multidisciplinary clinical review. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2002, 2, 71-85.	0.1	7
240	Butterbur: an evidence-based systematic review by the natural standard research collaboration. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2005, 5, 119-43.	0.1	7
241	Turmeric (<i>Curcuma longa</i>): An Evidence-Based Systematic Review by the Natural Standard Research Collaboration. <i>Alternative and Complementary Therapies</i> , 2011, 17, 225-236.	0.1	6
242	Clinical Cancer Informatics. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 195-196.	2.0	6
243	Commentary: Should Cost and Comparative Value of Treatments Be Considered in Clinical Practice Guidelines?. <i>Journal of Oncology Practice</i> , 2011, 7, 398-401.	2.5	6
244	A qualitative study of patient and provider perspectives on using web-based pain coping skills training to treat persistent cancer pain. <i>Palliative and Supportive Care</i> , 2018, 16, 155-169.	1.0	6
245	Use of Patient-Reported Outcomes to Understand & Measure the Patient Experience of Novel Cell and Gene Therapies. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1566-1575.	1.6	6
246	Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 77.e1-77.e8.	1.6	6
247	A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0253021.	2.5	6
248	Stakeholder Perceptions of Key Aspects of High-Quality Cancer Care to Assess with Patient Reported Outcome Measures: A Systematic Review. <i>Cancers</i> , 2021, 13, 3628.	3.7	6
249	Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS-25 domains. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29257.	1.5	6
250	Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning subscale among patients with advanced or metastatic breast cancer. <i>Cancer</i> , 2022, 128, 808-818.	4.1	6
251	Patient-reported outcome monitoring in a routine paediatric oncology setting: challenges and opportunities. <i>Lancet Oncology</i> , The, 2019, 20, 19-20.	10.7	5
252	Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 311-320.	1.2	5

#	ARTICLE	IF	CITATIONS
253	Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2. <i>Quality of Life Research</i> , 2021, , 1.	3.1	5
254	Wild Yam (Dioscoreaceae). <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2003, 3, 77-91.	0.1	5
255	Evaluating the implementation and impact of navigator-supported remote symptom monitoring and management: a protocol for a hybrid type 2 clinical trial. <i>BMC Health Services Research</i> , 2022, 22, 538.	2.2	5
256	Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2016, 11, 890-899.	1.1	4
257	Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 56.	1.9	4
258	Oncology in Transition. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2203.	7.4	4
259	Electronic Patient-Reported Outcomes After Thoracic Surgery: Toward Better Remote Management of Perioperative Symptoms. <i>Annals of Surgical Oncology</i> , 2021, 28, 1878-1879.	1.5	4
260	Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer. <i>Clinical Trials</i> , 2021, 18, 408-416.	1.6	4
261	Patient-Reported Outcomes Integrated Within an Electronic Medical Record in Patients With Head and Neck Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 842-848.	2.1	4
262	Safety assurances for dietary supplements policy issues and new research paradigms. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2005, 5, 3-15.	0.1	4
263	Safety Assurances for Dietary Supplements. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2005, 5, 3-15.	0.1	3
264	An Evidence-Based Systematic Review of Blessed Thistle (<i>Cnicus benedictus</i>) by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2008, 5, 422-437.	2.6	3
265	Seaweed, Kelp, Bladderwrack (<i>Fucus vesiculosus</i>): An Evidence-Based Systematic Review by the Natural Standard Research Collaboration. <i>Alternative and Complementary Therapies</i> , 2013, 19, 217-230.	0.1	3
266	Supervision Requirements in the 2020 Hospital Outpatient Prospective Payment System. <i>JAMA Oncology</i> , 2020, 6, 819.	7.1	3
267	Use of an Analytics and Electronic Health Record-Based Approach for Targeted COVID-19 Vaccine Outreach to Marginalized Populations. <i>JAMA Oncology</i> , 2021, 7, 1570.	7.1	3
268	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 447-456.	1.9	3
269	Interval Exercise Training (IET) Is Feasible and May Improve Cardiorespiratory Performance Prior to Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 2611-2611.	1.4	3
270	Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials. <i>Clinical Trials</i> , 2022, 19, 274-276.	1.6	3

#	ARTICLE	IF	CITATIONS
271	Reply to K. Kroenke et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3352-3352.	1.6	2
272	Evaluating Alternative Payment Models in Oncology. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2123.	7.4	2
273	Strategies to Achieve High-Value Oncology Care—A Beginning. <i>JAMA Oncology</i> , 2018, 4, 171.	7.1	2
274	Stakeholder perspectives on addressing adverse events from adjuvant cancer therapy: A qualitative study. <i>Cancer</i> , 2019, 125, 4471-4480.	4.1	2
275	Commentary on King-Kallimanis et al.: Inadequate measurement of symptomatic adverse events in immunotherapy registration trials. <i>Clinical Trials</i> , 2019, 16, 327-328.	1.6	2
276	Effect of abiraterone acetate (AA) on patient-reported pain in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: Results of longitudinal sensitivity analyses.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9618-9618.	1.6	2
277	Kava monograph: a clinical decision support tool. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2002, 2, 65-91.	0.1	2
278	An evidence-based systemic review Echinacea <i>E. angustifolia</i> DC, <i>E. pallida</i> , <i>E. purpurea</i> by the Natural Standard Research Collaboration. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2005, 5, 57-88.	0.1	2
279	Marshmallow (<i>Althaea officinalis</i> L.) Monograph. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2003, 3, 71-81.	0.1	2
280	An Evidence-Based Systematic Review of Passion Flower (<i>Passiflora Incarnata</i> L.) by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2008, 5, 310-340.	2.6	1
281	Cancer Care Research in North Carolina. <i>North Carolina Medical Journal</i> , 2014, 75, 248-252.	0.2	1
282	Development of the US NCI patient-reported outcomes version of the common terminology criteria for adverse events. <i>Annals of Oncology</i> , 2015, 26, vii26.	1.2	1
283	MR/Ultrasound Fusion-Guided Biopsy in Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 367.	7.4	1
284	Patient-related outcomes for metastatic prostate cancer. <i>Lancet Oncology</i> , The, 2015, 16, 477-478.	10.7	1
285	Appropriate Use of Antiemetics to Prevent Chemotherapy-Induced Nausea and Vomiting. <i>JAMA Oncology</i> , 2017, 3, 307.	7.1	1
286	Nurse, oncologist, and patient impressions of electronic symptom monitoring via patient-reported outcomes in community oncology practices: Qualitative results from the U.S. national PRO-TECT trial (AFT-39, NCT03249090).. <i>Journal of Clinical Oncology</i> , 2020, 38, 7044-7044.	1.6	1
287	Expectations for specialized knowledge in oncology: time to reassess. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 263-263.	4.3	0
288	Hops (<i>Humulus lupulus</i>): An Evidence-Based Systematic Review by the Natural Standard Research Collaboration. <i>Alternative and Complementary Therapies</i> , 2012, 18, 98-108.	0.1	0

#	ARTICLE	IF	CITATIONS
289	Reply to E. Grunfeld. <i>Journal of Oncology Practice</i> , 2015, 11, 347-347.	2.5	0
290	Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps. <i>JAMA Health Forum</i> , 2021, 2, e210673.	2.2	0
291	Targetable Action Points to Enhance Surgical Decision-Making. <i>Journal of the American College of Surgeons</i> , 2021, 233, e105.	0.5	0
292	Statewide Geographic Variation and Impact of Center Expertise upon Outcomes for Adults with Acute Myeloid Leukemia (AML) in North Carolina. <i>Blood</i> , 2015, 126, 4479-4479.	1.4	0
293	Pediatric Patient-Reported Symptom Tracking in Oncology (Pedi-PReSTO): A Feasibility Study. <i>Blood</i> , 2018, 132, 2290-2290.	1.4	0
294	Reply to "Another look at floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning subscale and possible solutions". <i>Cancer</i> , 2022, 128, 2386-2387.	4.1	0